The company is indeed facing operational difficulties, said the Chairman of Chongqing Zhifei Biological Products: there are discrepancies in internal forecasts | Highlights from the Earnings Conference.

① Regarding the current predicament of the company, the Chairman of Chongqing Zhifei Biological Products, Jiang Rensheng, candidly stated during the Earnings Conference that internal responsibility factors are more significant, and management is reflecting deeply. ② The company stated that it is addressing the current difficulties by communicating with partners, reducing the procurement quantity of agency products, and strengthening collection assessments.

cls.cnMay 9 20:34

The 75-year-old Chairman of the listed company shows off his muscles bare-chested, endorsing his own products and giving it his all.

① The Chairman of Sichuan Kelun Pharmaceutical, Liu Gexin, personally took charge as the spokesperson for the company's health product, showcasing his muscles. ② The company stated that the Chairman has been using this product and has maintained long-term discipline, and in the future, will launch other health products. ③ Industry insiders indicated that ergothioneine is extracted biologically, and can now also be produced through synthetic biology methods, having antioxidant properties, among others.

cls.cnMay 9 14:36

Xiamen C&D Inc. enters the restructuring of Tech-bank Food, stock price fluctuates with a late-session surge as a respectful initial increase.| Quick read of the announcement.

① Tech-bank Food has made substantial progress in its restructuring, with a consortium led by Xiamen Jianfa Real Estate Co., Ltd. getting involved; ② Industry investors will each acquire 0.2 billion newly allocated shares of the company at a price of 1.85 yuan per share, corresponding to an investment amount of 0.37 billion yuan.

cls.cnMay 9 00:02

It is expected that the delivery growth rate of Innovative Drugs will significantly increase. The chairman of Yifan Pharmaceutical stated, "The certainty of this year's performance is relatively high" | Direct coverage of the Earnings Conference.

1. Yifan Pharmaceutical expects that the shipment volumes of Yilishu and Yinikang will see significant growth by 2025 during the Earnings Conference. 2. Chairman Cheng Xianfeng stated that the company is expanding into the developed markets of Europe and America through Yilishu, while also continuing to focus on core therapeutic areas and promoting global research and development collaboration for key projects in the pipeline.

cls.cnMay 8 21:08

Holiday Reading | Novo-Nordisk A/S Halved: Why is it Difficult for Pharmaceutical Stocks to Achieve High Valuations?

The increase and performance of China Meheco Group stocks this year is still ranked relatively high among All Sectors. The logic of gaining incremental growth through international expansion is gradually being realized, as Chinese companies' products are becoming increasingly popular. Overseas leading MNCs also tend to come to China to discover good early-stage Assets, and many leading companies have gradually crossed the profitability breakeven point. The entire Industry is still in a prosperous phase.

It really is the Hong Kong stock market circle.May 3 15:28

The formerly hot stock with 13 consecutive limits has today hit a trading halt. Many companies faced a "no-notice Special Treat" Bearish surprise. | Quick read of the announcement.

① Mubang High-Tech and TVZone Media announced for the first time at the last moment of the annual report disclosure that they faced a delisting risk warning due to the "Net income + revenue" indicators. ② Both companies previously estimated in their performance forecasts and the Exchange's inquiries that their revenue for 2024 would exceed the indicator red line of 0.3 billion yuan. ③ AA Industrial Belting released an annual pre-loss announcement on the evening of the annual report disclosure, suddenly facing a trading suspension which resulted in its stock price hitting the daily limit down today.

cls.cnApr 30 12:10